Evidence map›Paper›PMID 33208985›Full record

ArticleJournal of theoretical & computational chemistry2020

Predicting mucin-type O-Glycosylation using enhancement value products from derived protein features.

Jonathon E Mohl, Thomas Gerken, Ming-Ying Leung

Abstract read
In one paragraph

Article in Journal of theoretical & computational chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jonathon E MohlDepartment of Mathematical Sciences and Border Biomedical Research Center, The University of Texas at El Paso, El Paso, TX 79968, USA.
Thomas GerkenDepartments of Biochemistry and Chemistry, Case Western Reserve University, Cleveland, OH, 44106, USA.
Ming-Ying LeungDepartment of Mathematical Sciences and Border Biomedical Research Center, The University of Texas at El Paso, El Paso, TX 79968, USA.

Funding

UTEP Border Biomedical Research CenterU54MD007592 · NIMHD · UNIVERSITY OF TEXAS EL PASO · PI Bibiana Marie Mancera · 2019 to 2026
$35.1M
Initiation and Regulation of Mucin-Type O-GlycosylationR01GM113534 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI GERKEN, THOMAS A · 2018 to 2023
$1.6M
NIGMS NIH HHS R01 GM113534NIMHD NIH HHS U54 MD007592
6 · The paper itself

Abstract

Mucin-type O-glycosylation is one of the most common post-translational modifications of proteins. This glycosylation is initiated in the Golgi by the addition of the sugar N-acetylgalactosamine (GalNAc) onto protein Ser and Thr residues by a family of polypeptide GalNAc transferases. In humans there are 20 isoforms that are differentially expressed across tissues that serve multiple important biological roles. Using random peptide substrates, isoform specific amino acid preferences have been obtained in the form of enhancement values (EV). These EVs alone have previously been used to predict O-glycosylation sites via the web based ISOGlyP (Isoform Specific O-Glycosylation Prediction) tool. Here we explore additional protein features to determine whether these can complement the random peptide derived enhancement values and increase the predictive power of ISOGlyP. The inclusion of additional protein substrate features (such as secondary structure and surface accessibility) was found to increase sensitivity with minimal loss of specificity, when tested with three different published

Indexed as

enhancement valueGalNAc transferasesISOGlyPO-glycosylation predictionpost-translational modification prediction

Identifiers

PMID33208985
PMCPMC7671581

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.